Related Experiment Video
Updated: Mar 22, 2026
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
Principal components analysis of agitation outcomes in Alzheimer's disease
Jerome A Yesavage1, Joy L Taylor2, Leah Friedman3
1Department of Veterans Affairs Health Care System, Palo Alto, CA, 94304, United States; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, United States; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, United States.
Background:
We developed a composite measure of agitation as a secondary outcome of change over time in the Citalopram for Agitation in Alzheimer's disease study (CitAD). CitAD demonstrated a positive effect of citalopram on agitation on the Neurobehavioral Rating Scale agitation subscale (NBRS-A). CitAD included additional agitation measures such as the Cohen-Mansfield Agitation Inventory and the Neuropsychiatric Inventory.
Methods:
We performed principal components analyses on change in individual item of these scales for the same, original CitAD subjects.
Results:
The first principal component accounted for 12.6% of the observed variance and was composed of items that appear to reflect agitation. The effect size for citalopram calculated using this component was 0.53 (95% CI 0.22-0.83) versus 0.32 for the NBRS-A (95% CI 0.01-0.62).
Conclusions:
Results suggest that a composite measure of change in agitation might be more sensitive than change in a single primary agitation measure.
More Related Videos
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment
01:30Dementia
The progression of dementia is generally gradual....